---
document_datetime: 2025-07-18 15:26:58
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fampridine-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fampridine-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6461016
conversion_datetime: 2025-12-29 23:22:56.263904
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fampridine Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                  | Scope              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                             |
|-------------------------------------|--------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000243787 | Renewal - Accepted | 25/04/2025                          | 23/06/2025                                  |                                  | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Fampridine Accord in the approved |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          |                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        | indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000263624    | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.b Deletion of a test procedure for the active substance or a starting material/reagent/ intermediate, if an alternative test procedure is already authorised. - Accepted                                                      | 07/04/2025 | N/A        |                        |                                                                                                                               |
| Variation type IA_IN / EMA/VR/0000254180 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 24/02/2025 | N/A        | Annex II and PL        |                                                                                                                               |
| Variation type IB / EMA/VR/0000231573    | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                          | 12/12/2024 | 31/03/2025 | SmPC, Labelling and PL |                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|